205 related articles for article (PubMed ID: 15279701)
21. Distinct patterns of innate immune activation by clinical isolates of respiratory syncytial virus.
Levitz R; Gao Y; Dozmorov I; Song R; Wakeland EK; Kahn JS
PLoS One; 2017; 12(9):e0184318. PubMed ID: 28877226
[TBL] [Abstract][Full Text] [Related]
22. Human Respiratory Syncytial Virus: An Introduction.
Jorquera PA; Anderson L; Tripp RA
Methods Mol Biol; 2016; 1442():1-12. PubMed ID: 27464683
[TBL] [Abstract][Full Text] [Related]
23. Moderate local and systemic respiratory syncytial virus-specific T-cell responses upon mild or subclinical RSV infection.
de Waal L; Koopman LP; van Benten IJ; Brandenburg AH; Mulder PG; de Swart RL; Fokkens WJ; Neijens HJ; Osterhaus AD
J Med Virol; 2003 Jun; 70(2):309-18. PubMed ID: 12696123
[TBL] [Abstract][Full Text] [Related]
24. Respiratory syncytial virus and other respiratory viruses.
Welliver RC
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S6-10; discussion S10-2. PubMed ID: 12671447
[TBL] [Abstract][Full Text] [Related]
25. Respiratory syncytial virus induces indoleamine 2,3-dioxygenase activity: a potential novel role in the development of allergic disease.
Ajamian F; Wu Y; Ebeling C; Ilarraza R; Odemuyiwa SO; Moqbel R; Adamko DJ
Clin Exp Allergy; 2015 Mar; 45(3):644-59. PubMed ID: 25627660
[TBL] [Abstract][Full Text] [Related]
26. Innate immune responses to respiratory syncytial virus infection.
Mukherjee S; Lukacs NW
Curr Top Microbiol Immunol; 2013; 372():139-54. PubMed ID: 24362688
[TBL] [Abstract][Full Text] [Related]
27. Low neonatal Toll-like receptor 4-mediated interleukin-10 production is associated with subsequent atopic dermatitis.
Belderbos ME; Knol EF; Houben ML; van Bleek GM; Wilbrink B; Kimpen JL; Rovers M; Bont L
Clin Exp Allergy; 2012 Jan; 42(1):66-75. PubMed ID: 22092594
[TBL] [Abstract][Full Text] [Related]
28. The immune response to respiratory syncytial virus infection: friend or foe?
Welliver RC
Clin Rev Allergy Immunol; 2008 Apr; 34(2):163-73. PubMed ID: 17985249
[TBL] [Abstract][Full Text] [Related]
29. Benefit and harm from immunity to respiratory syncytial virus: implications for treatment.
Habibi MS; Openshaw PJ
Curr Opin Infect Dis; 2012 Dec; 25(6):687-94. PubMed ID: 23086186
[TBL] [Abstract][Full Text] [Related]
30. Alveolar-like Macrophages Attenuate Respiratory Syncytial Virus Infection.
Porto BN; Litvack ML; Cen Y; Lok I; Bouch S; Norris MJ; Duan W; Ackerley C; Post M; Moraes TJ
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696391
[TBL] [Abstract][Full Text] [Related]
31. The innate immune system of the perinatal lung and responses to respiratory syncytial virus infection.
Derscheid RJ; Ackermann MR
Vet Pathol; 2013 Sep; 50(5):827-41. PubMed ID: 23528938
[TBL] [Abstract][Full Text] [Related]
32. Immunological mechanisms of severe respiratory syncytial virus bronchiolitis.
Bont L; Kimpen JL
Intensive Care Med; 2002 May; 28(5):616-21. PubMed ID: 12029411
[TBL] [Abstract][Full Text] [Related]
33. Respiratory syncytial virus and other respiratory viruses during the first 3 months of life promote a local TH2-like response.
Kristjansson S; Bjarnarson SP; Wennergren G; Palsdottir AH; Arnadottir T; Haraldsson A; Jonsdottir I
J Allergy Clin Immunol; 2005 Oct; 116(4):805-11. PubMed ID: 16210054
[TBL] [Abstract][Full Text] [Related]
34. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
[TBL] [Abstract][Full Text] [Related]
35. How RSV Proteins Join Forces to Overcome the Host Innate Immune Response.
Van Royen T; Rossey I; Sedeyn K; Schepens B; Saelens X
Viruses; 2022 Feb; 14(2):. PubMed ID: 35216012
[TBL] [Abstract][Full Text] [Related]
36. Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial responses by modulating activation of interferon regulatory factor-3.
Yamamoto K; Yamamoto S; Ogasawara N; Takano K; Shiraishi T; Sato T; Miyata R; Kakuki T; Kamekura R; Kojima T; Tsutsumi H; Himi T; Yokota SI
Pharmacol Res; 2016 Sep; 111():804-814. PubMed ID: 27468646
[TBL] [Abstract][Full Text] [Related]
37. Factors Affecting the Immunity to Respiratory Syncytial Virus: From Epigenetics to Microbiome.
Fonseca W; Lukacs NW; Ptaschinski C
Front Immunol; 2018; 9():226. PubMed ID: 29515570
[TBL] [Abstract][Full Text] [Related]
38. Immune responses and disease enhancement during respiratory syncytial virus infection.
Openshaw PJ; Tregoning JS
Clin Microbiol Rev; 2005 Jul; 18(3):541-55. PubMed ID: 16020689
[TBL] [Abstract][Full Text] [Related]
39. Importance of Virus Characteristics in Respiratory Syncytial Virus-Induced Disease.
San-Juan-Vergara H; Peeples ME
Immunol Allergy Clin North Am; 2019 Aug; 39(3):321-334. PubMed ID: 31284923
[TBL] [Abstract][Full Text] [Related]
40. The innate immune response to RSV: Advances in our understanding of critical viral and host factors.
Sun Y; López CB
Vaccine; 2017 Jan; 35(3):481-488. PubMed ID: 27686836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
